ASH 2023 | ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the ongoing ADVANCE trial (NCT04268498), which is comparing treatment with carfilzomib, lenalidomide, and dexamethasone with or without daratumumab (Dara-KRd versus KRd) in patients with newly diagnosed multiple myeloma (NDMM). The study utilizes measurable residual disease (MRD) to determine eligibility for transplantation and whole genome sequencing (WGS) to uncover the underlying biology of sustained MRD negativity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
